SHANGHAI and HONG KONG, Oct. 5, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that it will present three programs at the 2024 Society of Immunology in Cancer Annual Meeting (SITC 2024) to be held in Houston from November 6-10, 2024.
Logo (PRNewsfoto/Antengene Corporation Limited)
Details of Poster Presentations:
ATG-201 (CD19 x CD3 T-cell Engager) Title: ATG-201, a novel "2+1" CD19-targeted T-cell Engager (TCE) for the treatment of B cell malignancies and B cell related autoimmune diseases Abstract Number: 1067 Poster Abstract Presentation at the SITC Immune Engineering Workshop Date:November 7, 2024 Time: 3:10 PM - 5:00 PM (Central Standard Time) 5:10 AM – 7:00 AM, Nov 8, 2024 (Beijing Time) Poster Presentation at the SITC 39th Annual Meeting Date: November 8, 2024 Time: 9:00 AM - 7:00 PM (Central Standard Time) 11:00 PM, Nov 8 – 9:00 AM, Nov 9, 2024 (Beijing Time)
ATG-107 (FLT3 x CD3 T-cell Engager) Title: ATG-107, a novel "2+1" CD3-based T-cell Engager (TCE) targeting FLT3, demonstrates potent preclinical efficacy for the treatment of AML Abstract Number: 1068 Poster Abstract Presentation at the SITC Immune Engineering Workshop Date:November 7, 2024 Time:3:10 PM - 5:00 PM (Central Standard Time) 5:10 AM – 7:00 AM, Nov 8, 2024 (Beijing Time) Poster Presentation at the SITC 39th Annual Meeting Date:November 9, 2024 Time:9:00 AM - 8:30 PM (Central Standard Time) 11:00 PM, Nov 9 – 10:30 AM, Nov 10, 2024 (Beijing Time)
ATG-106 (CDH6 x CD3 T-cell Engager) Title: ATG-106, a novel "2+1" format CDH6-targeted T-cell Engager (TCE), shows potent T cell dependent cytotoxicity and in vivo anti-tumor efficacy Abstract Number: 1069 Poster Presentation at the SITC 39th Annual Meeting Date: November 8, 2024 Time: 9:00 AM - 7:00 PM (Central Standard Time) 11:00 PM, Nov 8 – 9:00 AM, Nov 9, 2024 (Beijing Time)
About the AnTenGager™ Platform
The AnTenGager™ Platform is a proprietary "2+1" T cell engager (TCE) platform developed by Antengene. AnTenGager™ TCE simultaneously binds to disease-associated antigens (targets) and a unique conformational epitope on CD3 that expressed on T-cells. The bivalent binding to the targets enables detection and depletion of cells with low expression of the targets. In addition, AnTenGager™ TCE activates T cells in a target-dependent manner so that it demonstrates a lower risk of systemic CD3 activation and cytokine release syndrome (CRS), potentially paving the way for their use in autoimmune diseases, hematological malignancies, and solid tumors.
Our extensive and diverse pipeline features promising TCEs that aim to address unmet medical needs in autoimmune diseases and hematology/oncology, with best-in-class/first-in-class potential. A few of our lead programs in the IND-enabling stage include ATG-201, a CD19 x CD3 TCE for B cell related autoimmune diseases; ATG-102, a LILRB4 x CD3 TCE for acute myeloid leukemia (AML) and chronic myelomonocytic leukemia; ATG-106, a CDH6 x CD3 TCE for ovarian cancer and kidney cancer; ATG-107, a FLT3 x CD3 TCE for AML; and ATG-110, a LY6G6D x CD3 TCE for microsatellite stable (MSS) colorectal cancer.
About Antengene
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders".
Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 29 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, and Australia.
Forward-looking statements
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2023, and the documents subsequently submitted to the Hong Kong Stock Exchange.
